ReviewExpert review of vaccines2009
SARS vaccines: where are we?
Review in Expert review of vaccines, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 4 syntheses or guidelines pooled it, 191 citations in OpenAlex.
- Efficacy and safety of COVID-19 vaccines.The Cochrane database of systematic reviews · 2022Pooled it
- Meta-analysis and comprehensive study of coronavirus outbreaks: SARS, MERS and COVID-19.Journal of infection and public health · 2021Pooled it
- A systematic review of SARS-CoV-2 vaccine candidates.Signal transduction and targeted therapy · 2020Pooled it
- COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.Frontiers in immunology · 2020Pooled it
- Bayesian spatio-temporal modeling of severe acute respiratory syndrome in Brazil: A comparative analysis across pre-, during, and post-COVID-19 eras.Infectious Disease Modelling · 2025Article
- Nucleic acid vaccine candidates encapsulated with mesoporous silica nanoparticles against MERS-CoV.Human vaccines & immunotherapeutics · 2024Article
- Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines.Frontiers in cellular and infection microbiology · 2024Review
- Physicochemical properties-based hybrid machine learning technique for the prediction of SARS-CoV-2 T-cell epitopes as vaccine targets.PeerJ. Computer science · 2024Article
- COVID-19 vaccines: current and future challenges.Frontiers in pharmacology · 2024Review
- Immunization against Medically Important Human Coronaviruses of Public Health Concern.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Review
- Article
- Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2.Oxford open immunology · 2023Review
- Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines.Frontiers in immunology · 2023Review
- A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Review
- SARS-CoV-2 in the pancreas and the impaired islet function in COVID-19 patients.Emerging microbes & infections · 2022Article
- Vaccines platforms and COVID-19: what you need to know.Tropical diseases, travel medicine and vaccines · 2022Review
- Adverse events reported after administration of BNT162b2 and mRNA-1273 COVID-19 vaccines among hospital workers: a cross-sectional survey-based study in a Spanish hospital.Expert review of vaccines · 2022Article
- Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2.PLoS computational biology · 2022Article
- Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis.Vaccines · 2022Review
- Machine Learning Techniques for the Prediction of B-Cell and T-Cell Epitopes as Potential Vaccine Targets with a Specific Focus on SARS-CoV-2 Pathogen: A Review.Pathogens (Basel, Switzerland) · 2022Review
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review, the current state of vaccine development against human severe acute respiratory syndrome (SARS) coronavirus, focusing on recently published data is assessed. We discuss which strategies have been assessed immunologically and which have been evaluated in SARS coronavirus challenge models. We discuss inactivated vaccines, virally and bacterially vectored vaccines, recombinant protein and DNA vaccines, as well as the use of attenuated vaccines. Data regarding the correlates of protection, animal models and the available evidence regarding potential vaccine enhancement of SARS disease are discussed. While there is much evidence that various vaccine strategies against SARS are safe and immunogenic, vaccinated animals still display significant disease upon challenge. Current data suggest that intranasal vaccination may be crucial and that new or combination strategies may be required for good protective efficacy against SARS in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.